Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod
August 25 2020 - 7:00AM
Business Wire
Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene
regulatory and immunotherapeutic drugs utilizing spherical nucleic
acid (SNA™) technology, announced that it will host a virtual KOL
meeting on Wednesday, September 16th, 2020 from 10:30 am-12 pm ET
to discuss the preliminary Phase 1b efficacy and safety data for
cavrotolimod, Exicure’s SNA-enabled TLR9 agonist for solid
tumors.
Phase 1b Principal Investigators, Dr. Steven O’Day and Dr.
Shailender Bhatia, will join Exicure’s leadership team in
discussing the clinical results and progress to date.
Steven J. O’Day, MD, is the Executive Director of the John Wayne
Cancer Institute and Cancer Clinic, and Director of Providence Los
Angeles Regional Research. He is the Professor of Medical Oncology,
Director of Immuno-Oncology, and Director of Clinical Research at
the John Wayne Cancer Institute at Providence Saint John’s Health
Center. Shailender Bhatia, MD, is an Associate Professor at the
University of Washington School of Medicine and an Assistant
Professor of the Clinical Research Division at the Fred Hutchinson
Cancer Research Center.
A live webcast will be available in the Events and Presentations
section of Exicure’s website on September 16th at 10:30 am ET. An
archived version will be available on the company website following
the event. To RSVP for the event, please use the link here
(https://troutaccess.com/investor.php/c/ExicureKOLDay2020) or email
rjohn@troutgroup.com.
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on our
proprietary spherical nucleic acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN, an
SNA–based therapeutic candidate, for the treatment of Friedreich’s
ataxia (FA). Exicure's therapeutic candidate cavrotolimod is in a
Phase 1b/2 trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA.
For more information, visit Exicure’s website at
www.exicuretx.com.
Exicure Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements in this press release other than statements of
historical fact could be deemed forward looking including, but not
limited to, statements regarding the anticipated and potential
impact of the COVID-19 pandemic on the company’s business and
operations, including its ongoing Phase 1b/2 clinical trial for
cavrotolimod (AST-008); the company’s plans, initiatives and
expectations in light of and in response to the COVID-19 pandemic;
the company’s expectations regarding its ability to adapt its
business to the evolving COVID-19 pandemic, mitigate its impacts on
the business and maintain business continuity; the design, timing
and results of its Phase 1b/2 clinical trial of cavrotolimod
(AST-008) including patient enrollment expectations and opening of
additional clinical trial sites; the initiation, timing and results
of its other preclinical studies and clinical trials, including
XCUR-FXN; the potential of the company’s SNA technology to address
the genetic challenges posed by Friedreich’s ataxia and other
neurological conditions; the potential of the company’s
collaborations and R&D efforts; and the company’s anticipated
cash runway. The forward-looking statements in this press release
speak only as of the date of this press release, and the company
undertakes no obligation to update these forward-looking
statements. Forward-looking statements are based on management’s
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: the risks that the ongoing COVID-19
pandemic may disrupt the company’s business and/or the global
healthcare system more severely than it has to date or more
severely than anticipated, which may have the effect of impacting
or delaying the company’s ongoing Phase 1b/2 clinical trial;
unexpected costs, charges or expenses that reduce the company’s
capital resources; the company’s preclinical or clinical programs
do not advance or result in approved products on a timely or cost
effective basis or at all; the cost, timing and results of clinical
trials; that many drug candidates do not become approved drugs on a
timely or cost effective basis or at all; the ability to enroll
patients in clinical trials; possible safety and efficacy concerns;
regulatory developments; and the ability of the company to protect
its intellectual property rights. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause the company’s actual results to differ from those contained
in the forward-looking statements, see the section titled “Risk
Factors” in the company’s Annual Report on Form 10-K for the year
ended December 31, 2019, as updated by the company’s subsequent
filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and the company undertakes no duty to update this information,
except as required by law. In addition, the COVID-19 pandemic and
the associated containment efforts have had a serious adverse
impact on the economy, the severity and duration of which are
uncertain. Government stabilization efforts will only partially
mitigate the consequences. The extent and duration of the impact on
the company’s business and operations is highly uncertain, and that
impact includes effects on its clinical trial operations and supply
chain. Factors that will influence the impact on the company’s
business and operations include the duration and extent of the
pandemic, the extent of imposed or recommended containment and
mitigation measures, and the general economic consequences of the
pandemic. The COVID-19 pandemic could have a material adverse
impact on the company’s business, operations and financial results
for an extended period of time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200825005258/en/
For Media: MacDougall Karen Sharma 781-235-3060
ksharma@macbiocom.com
For Investors: Thomas Hoffmann Solebury Trout
+1-646-378-2931 thoffmann@troutgroup.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024